share_log

藥明生物：截至二零二四年六月三十日止六個月之中期業績公告

WUXI BIO: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEX ·  Aug 21 20:00
Summary by Futu AI
藥明生物公布2024年上半年業績，收益輕微增長1.0%至人民幣8,574.2百萬元，毛利率下降2.8個百分點至39.1%，純利大幅下滑23.9%至人民幣1,780.3百萬元。公司擁有人應佔純利更是下降33.9%至人民幣1,499.1百萬元。儘管面臨挑戰，藥明生物保持穩健業務發展，項目數增長顯著，綜合項目總數增至742個。董事會決定不派發中期股息。展望未來，藥明生物將繼續投資提升能力及規模，以支持持續增長。
藥明生物公布2024年上半年業績，收益輕微增長1.0%至人民幣8,574.2百萬元，毛利率下降2.8個百分點至39.1%，純利大幅下滑23.9%至人民幣1,780.3百萬元。公司擁有人應佔純利更是下降33.9%至人民幣1,499.1百萬元。儘管面臨挑戰，藥明生物保持穩健業務發展，項目數增長顯著，綜合項目總數增至742個。董事會決定不派發中期股息。展望未來，藥明生物將繼續投資提升能力及規模，以支持持續增長。
Wuxi Bio announced its business performance for the first half of 2024, with a slight increase in revenue of 1.0% to RMB 857.42 million, a decrease in gross margin of 2.8 percentage points to 39.1%, and a significant decline in net profit of 23.9% to RMB 178.03 million. The company's attributable net profit also decreased by 33.9% to RMB 149.91 million. Despite facing challenges, Wuxi Bio maintained steady business development with a significant increase in the number of projects, bringing the total number of projects to 742. The board of directors has decided not to distribute interim dividends. Looking ahead, Wuxi Bio will continue to invest in enhancing capabilities and scale to support sustainable growth.
Wuxi Bio announced its business performance for the first half of 2024, with a slight increase in revenue of 1.0% to RMB 857.42 million, a decrease in gross margin of 2.8 percentage points to 39.1%, and a significant decline in net profit of 23.9% to RMB 178.03 million. The company's attributable net profit also decreased by 33.9% to RMB 149.91 million. Despite facing challenges, Wuxi Bio maintained steady business development with a significant increase in the number of projects, bringing the total number of projects to 742. The board of directors has decided not to distribute interim dividends. Looking ahead, Wuxi Bio will continue to invest in enhancing capabilities and scale to support sustainable growth.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.